Due to the increasing incidence of diabetes, obesity and metabolic disease in the United States, it is estimated that one in four patients has some form of fatty liver disease. The impact of this on the healthcare system has been realized and is likely to increase over time. As primary care physicians continue to see […]

In an interview with PharmaShots, Dr. Jim Woody, MD, Ph.D., Chief Executive Officer at 180 Life Sciences shared his insights on the Phase 2b study of anti-TNF for the treatment of the early Dupuytren’s disease. Shots: 180 Life Sciences used anti-TNF to treat early Dupuytren’s disease and the Phase 2b study is complete.

As many good and longstanding friendships do, it all started with beer. If you trace the roots of the partnership between Kyowa Kirin North America and the La Jolla Institute for Immunology deep enough, you’ll find the remnant hulls of seeds planted by research scientists and fertilized by beer. It was the mid-1980s, when research […]